Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Wellie Adlaon

Internal Medicine Tishomingo, OK Medical Doctor

NPI 1245326925 CMS profile 146973

508 E 24Th St, Tishomingo, OK 73460

Open in the dashboard

General payments

$7,093

557 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Wellie Adlaon of Tishomingo, OK is reported in the CMS Open Payments database as having received $7,093 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,149 89
2022 General $1,869 162
2021 General $1,783 140
2020 General $1,259 89
2019 General $1,034 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wellie Adlaon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Wellie Adlaon were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Wellie Adlaon Internal Medicine median Middle half National median
2019 $1,034 $159 $48–$570 $163
2020 $1,259 $119 $33–$402 $114
2021 $1,783 $135 $37–$521 $132
2022 $1,869 $141 $42–$496 $149
2023 $1,149 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Otsuka America Pharmaceutical, Inc. $1,573 119 payments
  2. Janssen Pharmaceuticals, Inc $856 70 payments
  3. Lundbeck LLC $782 38 payments
  4. AbbVie, Inc. $728 74 payments
  5. Teva Pharmaceuticals USA, Inc. $623 42 payments
  6. Vanda Pharmaceuticals Inc. $539 33 payments
  7. ITI, Inc. $412 51 payments
  8. Indivior Inc. $391 32 payments
  9. Sunovion Pharmaceuticals Inc. $368 38 payments
  10. Allergan Inc. $297 28 payments
  11. Other $524 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $7,093 557 payments
Products named General payments · program years 2019–2023
  1. ABILIFY MAINTENA $1,608 104 payments
  2. REXULTI $1,259 95 payments
  3. INVEGA SUSTENNA $816 67 payments
  4. VRAYLAR $685 71 payments
  5. HETLIOZ $539 33 payments
  6. FANAPT $539 33 payments
  7. CAPLYTA $412 51 payments
  8. PERSERIS $391 32 payments
  9. AUSTEDO $383 26 payments
  10. LATUDA $368 38 payments
  11. Other $2,402 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

1,267

Median for Internal Medicine: 777

Drug cost

$114,229

Median for Internal Medicine: $73,373

Branded share of claims

11.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Perseris Risperidone Brand 19 $54,060
Ozempic Semaglutide Brand 18 $17,513
Jardiance Empagliflozin Brand 13 $8,905
Eliquis Apixaban Brand 12 $7,586
Trintellix Vortioxetine Hydrobromide Brand 14 $6,762
Lurasidone Hcl Generic 19 $3,458
Fluphenazine Hcl Generic 14 $1,880
Aripiprazole Generic 48 $1,328
Haloperidol Generic 26 $1,149
Gabapentin Generic 81 $917

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record